Lancet Oncology

1.    A Phase I, First-in-Human, Trial of RRx-001, A Novel Oxidative Epigenetic Agent, in Patients with Advanced Cancer
Tony Reid, Bryan Oronsky, Jan Scicinski, Curt Scribner, Susan Knox, Shoucheng Ning, Donna M. Peehl, Ron Korn, Meaghan Stirn, Gary R. Fanger, Corey A. Carter, Arnold Oronsky, Michael J. Taylor, William L. Fitch, Pedro Cabrales, Howard A Burris III, Michelle M. Kim, Christopher Lao, Jeffrey Infante
The Lancet Oncology 2015 Sep;16(9):1133-42
2.    Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, Peehl DM, Korn R, Stirn M, Carter CA, Oronsky A, Taylor MJ, Fitch WL, Cabrales P, Kim MM, Burris HA 3rd, Lao CD, Abrouk NE, Fanger GR, Infante JR.
Lancet Oncol. 2015 Sep;16(9):1133-42.

3.     Epigenetic approaches to overcoming chemotherapy resistance
Strauss J, Figg WD.
Lancet Oncol. 2015 Sep;16(9) 1013-1015

4.    RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors
Oronsky B, Scicinski J, Cabrales P, Minchinton A.
Clin Epigenetics. 2016 May 11;8:53.

5.    A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells
Sharma Das D, Ray A, Das A, Song Y, Tian Z, Oronsky B, Richardson P, Scicinski J, Chauhan D, Anderson KC.
Leukemia 2016 May 24.

6.    A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?
Cabrales P, Scicinski J, Reid T, Kuypers F, Larkin S, Fens M, Oronsky A, Oronsky B.
Med Oncol. 2016 Jul;33(7):63.

7.    RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells
Oronsky B, Scicinski J, Reid T, Oronsky A, Carter C, Oronsky N, Cabrales P.
Discov Med. 2016 Apr;21(116):251-65.

8.     Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy
Oronsky B, Carter C, Scicinska A, Oronsky A, Oronsky N, Lybeck M, Scicinski J.
Oncotarget. 2016 Feb 23;7(8):9041-5.

9.    Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity
Zhao H, Ning S, Scicinski J, Oronsky B, Knox SJ, Peehl DM.
Oncotarget. 2015 Dec 22;6(41):43172-81.

10.    Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
Ning S, Sekar TV, Scicinski J, Oronsky B, Peehl DM, Knox SJ, Paulmurugan R.
Oncotarget. 2015 Aug 28;6(25):21547-56.

11.    NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001
Scicinski J, Oronsky B, Ning S, Knox S, Peehl D, Kim MM, Langecker P, Fanger G.
Redox Biol. 2015 Dec;6:1-8

12.    From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria
Yalcin O, Oronsky B, Carvalho LJ, Kuypers FA, Scicinski J, Cabrales P.
Malar J. 2015 May 28;14:218.

13.    Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock
Brouse C, Ortiz D, Su Y, Oronsky B, Scicinski J, Cabrales P.
Asian J Transfus Sci. 2015 Jan-Jun;9(1):55-60.

14.    Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy
Ning S, Bednarski M, Oronsky B, Scicinski J, Knox SJ.
Biochem Biophys Res Commun. 2014 May 9;447(3):537-42.

15.    Development of methods for the bioanalysis of RRx-001 and metabolites
Scicinski J, Oronsky B, Cooper V, Taylor M, Alexander M, Hadar R, Cosford R, Fleischmann T, Fitch WL.
Bioanalysis. 2014 Apr;6(7):947-56.

16.     The implications of hyponitroxia in cancer
Oronsky B, Fanger GR, Oronsky N, Knox S, Scicinski J.
Transl Oncol. 2014 Apr;7(2):167-73

17.     Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm
Paulmurugan R, Oronsky B, Brouse CF, Reid T, Knox S, Scicinski J.
Theranostics. 2013 May 25;3(6):437-47.

18.     Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent
Scicinski J, Oronsky B, Taylor M, Luo G, Musick T, Marini J, Adams CM, Fitch WL.
Drug Metab Dispos. 2012 Sep;40(9):1810-6.

19.     Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials
Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox SJ.
Cancer Res. 2012 May 15;72(10):2600-8.

1.    “No patient left behind”: an alternative to “the War on Cancer” metaphor
Oronsky BT, Carter CA, Oronsky AL, Salacz ME, Reid T.
Med Oncol. 2016 Jun;33(6):55.

2.    Rockets, radiosensitizers, and RRx-001: an origin story part I
Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S.
Discov Med. 2016 Mar;21(115):173-80.

3.    Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies
Carter CA, Zeman K, Day RM, Richard P, Oronsky A, Oronsky N, Lybeck M, Scicinski J, Oronsky B.
Oncotarget. 2016 Mar 19.

4.    RRx-001, A novel dinitroazetidine radiosensitizer
Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S.
Invest New Drugs. 2016 Jun;34(3):371-7.

5.    Confirmatory Trials In The Evaluation Of Anticancer Medicinal Products In Man—PFS2: A Measure Of Therapeutic Action-At-A-Distance
Oronsky B, Carter C, Reid T, Scicinski J, Oronsky A, Lybeck M, Caroen S, Stirn M, Oronsky N, Langecker P
Neoplasia 2015, 17(9): 716-722

6.    Episensitization: Defying Time’s Arrow
Oronsky BT, Oronsky AL, Lybeck M, Oronsky NC, Scicinski JJ, Carter C, Day RM, Rodriguez Orengo JF, Rodriguez-Torres M, Fanger GF, Reid TR
Front Oncol. 2015 Jun 11;5:134

7.    The war on cancer: a military perspective
Oronsky B, Carter C, Mackie V, Scicinski J, Oronsky A, Oronsky N, Caroen S, Parker C, Lybeck M, Reid T
Front Oncol. 2014; 4: 387

8.    Rewriting the Epigenetic Code for Tumor Resensitization:  A Review
Oronsky B, Oronsky N, Scicinski J, Fanger G, Lybeck M, Reid T
Trans. Onc. 2014, 7, 626-631

9.    Follow the ATP: Tumor energy production. A Perspective
Oronsky B, Oronsky N, Fanger GR, Parker CW, Caroen SZ, Lybeck M, Scicinski J
Anticancer Agents Med Chem 2014;14(9):1187-98

10.    Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment
Oronsky B, Oronsky N, Knox S, Fanger GR, Scicinski J
Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1187-1198

11.    The Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents
Oronsky BT, Reid T, Knox SJ, Scicinski JJ
Trans. Onc. 2012, 21, 226

12.    Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review
Oronsky BT, Scicinski JJ, Reid T, Knox S
Trans. Onc. 2012, 5, 133

13.    Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review
Oronsky B, Knox S, Scicinski J
Trans. Onc. 2012, 5, 66

14.    Six Degrees of Separation: The Oxygen Effect in the Development of Radiosensitizers
Oronsky B, Knox S, Scicinski J
Trans. Onc. 2011, 4, 256

1.    Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
Carter CA, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C.
Respir Med Case Rep. 2016 Apr 24;18:62-5.

2.    Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial
Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA, Oronsky A, Knox SJ, Caroen S, Oronsky B, Scicinski J, Lawrence TS, Lao CD.
Transl Oncol. 2016 Apr;9(2):108-13.

3.    Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?
Carter CA, Scicinski JJ, Lybeck HE, Oronsky BT.
Case Rep Oncol. 2016 Apr 23;9(1):246-8.

4.    Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001
Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C.
Case Rep Oncol. 2016 Mar 10;9(1):164-70.

5.    The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis
Carter CA, Browning R, Oronsky BT, Scicinski JJ, Brzezniak C.
Case Rep Oncol. 2016 Jan 27;9(1):68-75.

6.    Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization
Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Cabrales P, Reid T, Degesys A, Jenkins J, Brzezniak C.
Case Rep Oncol. 2016 Jan 28;9(1):62-7.

7.    RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report
Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA.
Case Rep Oncol. 2016 Jan 15;9(1):45-50.

8.    Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases
Kim MM, Parmar H, Cao Y, Knox SJ, Oronsky B, Scicinski J, Lawrence TS, Lao CD.
Neuro Oncol. 2016 Mar;18(3):455-6.

9.    Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor
Carter CA, Degesys A, Oronsky B, Scicinski J, Caroen SZ, Oronsky AL, Reid T, Cabrales P, Roswarski J.
Case Rep Oncol. 2015 Oct 30;8(3):461-5.

10.    Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients
Reid T, Dad S, Korn R, Oronsky B, Knox S, Scicinski J.
Case Rep Oncol. 2014 Jan 24;7(1):79-85. doi: 10.1159/000358382.

1.    Episensitization: A New Word for A New Concept
Bryan T. Oronsky, Arnold L. Oronsky, Michelle Lybeck, Neil C. Oronsky, Jan J. Scicinski, Corey Carter, Gary R. Fanger, Tony R. Reid
Drug Discovery in Cancer Epigenetics ed. Egger, G, 2016

2.    Discovery and Development of RRx-001, a Novel Nitric Oxide and ROS Mediated Epigenetic Modulator
Jan Scicinski, Bryan Oronsky, Shoucheng Ning, Gary R Fanger, Susan J Knox, Mark Bednarski
Nitric Oxide and Cancer: Pathogenesis and Therapy ed. Bonavida, B, 2015

3.    Hyponitroxia in Cancer
Bryan Oronsky, Neil Oronsky, Michelle Lybeck, Gary Fanger, Jan Scicinski
Nitric Oxide and Cancer: Pathogenesis and Therapy ed. Bonavida, B, 2015

1.     The Hypoxia-Selective Epigenetic Agent, RRx-001, Triggers Apoptosis and Overcomes Drug-Resistance in Multiple Myeloma Cells
Chauhan D.
ASH 2015, oral presentation, Orlando FL, December 5-8, 2015

2.     ‘RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing Phase 2 colorectal cancer study, “ROCKET”’
Reid T, Fisher G, Carter C, Cho-Phan C, Kunz P, Oronsky B, Fanger G, Caroen S, Parker P, Scicinski J
AACR, Chromatin and Epigenetics in Cancer, 2015, Atlanta, GA, September 24 – 27, 2015

3.     ‘Restoring Efficacy of Immunotherapy Treatments in Oncology with Radical Oxygen and Nitrogen Based Epigenetic Drugs’
Scicinski J,
Invited Presentation at Stem Cells Regenerative Medicine Congress 2015, Washington, D.C., September 2 – 3, 2015

4.    Early results from a phase 2 study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer
AACR 2015 Abstract Control Number: 8836
Ann Oncol. 2015 Mar;26(suppl 2):ii4-ii5

5.    RRx-001 Oxidation of Redox Sensitive Protein Thiols in Tumors Measured by Gd-LC7-SH Enhanced MRI In Preclinical Tumor Models
Natarajan Raghunand, Jan Scicinski, Bryan Oronsky, Bhumasamudram Jagadish, Eugene A. Mash, Ronald L. Korn
ISMRM 2015

6.    The development of RRx-001, a novel nitric-oxide-mediated epigenetically active anticancer agent
Jan Scicinski, George Fisher, Corey Carter, Cheryl Cho-Phan, Pamela Kunz, Shoucheng Ning, Susan Knox, Bryan Oronsky, Scott Caroen, Christopher Parker, Gary Fanger, Tony Reid
Invited Presentation at 4th International Workshop on Nitric Oxide in Cancer Therapy, Mar 13 – 14, 2015, Seville, Spain

7.    Early results from a phase 2 study of RRx-001, a novel epigenetic modulator, show resensitization to irinotecan in colorectal cancer
Tony Reid, George Fisher, Corey Carter, Cheryl Cho-Phan, Pamela Kunz, Bryan Oronsky, Gary R. Fanger, Scott Caroen, Christopher Parker, Jan Scicinski
5th Clinical Epigenetics International Meeting. March 5th – 6th, 2015 – Düsseldorf, Germany

8.    Early Results: “ROCKET” a phase II Study of RRx-001, a novel triple epigenetic inhibitor, Resensitization to Irinotecan in Colorectal Cancer
Corey Carter, Tony Reid, George Fisher, Cheryl Cho-Phan, Pamela Kunz, Heidi Kaiser, Bryan Oronsky, Gary Fanger, Scott Caroen, Christopher Parker, Jan Scicinski
13th International Congress on Targeted Anticancer Therapies: TAT 2015. Paris, France, mar 2-4, 2015

9.    RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 “ROCKET” study
Tony Reid, George Fisher, Corey Carter, Cheryl Cho-Phan, Pamela Kunz, Shoucheng Ning, Susan Knox, Bryan Oronsky, Scott Caroen, Christopher Parker, Gary Fanger, Jan Scicinski*
17th Annual Symposium on Anti-Angiogenesis and immune therapies, La Jolla, Feb 19 – 21, 2015

10.    RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 “ROCKET” study
Tony Reid, Jennifer Carney, Keola Beale, Clayton Chan, Huy Nguyen, Meaghan Stirn, Shoucheng Ning, Susan Knox, Bryan Oronsky, Jan Scicinski, Scott Caroen, Christopher Parker, Gary Fanger, George Fisher
AACR Translation of the Cancer Genome Conference, San Francisco, California, February 7 – 9, 2015

11.    Anti-Myeloma Activity of a Novel Free Radical Inducer RRx-001
Deepika Sharma Das , Ze Tian , Arghya Ray , Durgadevi Ravillah , Yan Song , Paul G. Richardson , Bryan Oronsky , Jan Scicinski , Dharminder Chauhan, Kenneth C. Anderson
Blood, 2014, 124 (21) 4712

12.    RRx-001 An EXO-based Epigenetic Anti-Cancer Agent in Phase 2 Clinical Trials
Pedro Cabrales, Tony Reid, Bryan Oronsky, Jan Scicinski, Dharminder Chauchan, Christopher Parker, Scott Caroen, Gary Fanger
ISEV2014 Educational Event: Extracellular Vesicles and Biofluid Biopsies/Companion Diagnostics Conference

13.    A phase 1 trial and pharmacokinetic study of RRx-001, a novel ROS-mediated pan-epigenetic agent
Reid TR, Oronsky B, Infante JR, Burris HA, Scribner C, Knox SJ, Stephens JL, Fanger G, Scicinski J
J Clin Oncol 2014 32:5s (suppl; abstr 2578)

14.    Resensitization to Previous Chemotherapy with the Novel Hypomethylating Anticancer Agent RRx-001
Reid T, Knox SJ, Ning S, Peehl D, Oronsky B, Stephens J, Fanger G, Korn R, Dad S, Scicinski J
16th International Symposium on Anti-Angiogenic Therapy, La Jolla, Feb 6 – 8, 2014

15.    RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI In preclinical tumor models
Raghunand N, Scicinski J, Oronsky B, Guntle G, Bruckheimer E, Korn R
Proceedings: AACR 105th Annual Meeting 2014– Apr 5-9, 2014; San Diego, CA, Abstr 2068

16.    RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase
Cabrales P, Oronsky B, Scicinski J
Proceedings: AACR 105th Annual Meeting 2014– Apr 5-9, 2014; San Diego, CA, Abstr 1420

17.    Molecular imaging of RRx-001-induced oxidative stress in Nrf2-luciferase expressing SCC VII tumors in mice
Ning S, Sekar TV, Paulmurugan R, Scicinski J, Oronsky B, Peehl D, Knox SJ
Proceedings: AACR 105th Annual Meeting 2014– Apr 5-9, 2014; San Diego, CA, Abstr 906

18.    ‘High resolution MS proves that the developmental cancer drug, RRx-001, alkylates the hemoglobin beta chain’
Fitch B, McLaughlin T, Fens M, Scicinski J
2013 American Chemical Society, Western Regional Meeting, Abstract WRM 267 (Oral presentation)

19.    ‘Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent’
Reid T, Infante J, Paul A, Burris H, Oronsky B, Scribner C, Knox S, Stephens J, Santini J, Scicinski J
Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1 (LB-86)
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC
Also presented at: 15th International Symposium on Anti-Angiogenic Therapy, La Jolla, Jan 31- Feb 2, 2013

20.    ‘RRx-001: A novel hypoxia activated nitric oxide generating vascular disrupting agent (VDA)’
Oronsky B, Ning S, Knox S, Cabrales P, Minchinton A, Kuypers F, Fens M, Santini J, Reid T, Scicinski J
15th International Symposium on Anti-Angiogenic Therapy, La Jolla, Jan 31- Feb 2, 2013

21.    ‘Antivascular activity of RRx-001 in SCCVII and U87 tumors’
Scicinski J, Oronsky B, Ning S, Minchinton A, Knox S
15th International Symposium on Anti-Angiogenic Therapy, La Jolla, Jan 31- Feb 2, 2013

22.    ‘RRx-001, a Hypoxia Activated, Nitric Oxide generating cytotoxic agent: Phase 1 study results’
Scicinski J
Presentation at 3rd International Workshop on Nitric Oxide in Cancer Therapy, May 31 – Jun3 1, 2013, Kingston Ontario

23.    ‘RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors’
Scicinski J, Oronsky B, Ning S, Minchinton A, Knox S
Cancer Research: April 15, 2012; Volume 72, Issue 8, Supplement 1 (4371)
Proceedings: AACR 103rd Annual Meeting 2012– Mar 31-Apr 4, 2012; Chicago, IL

24.    ‘Treatment with a Novel Dinitroazetidine, ABDNAZ, Improves Nitrite Reductase Activity of Sickle Red Blood Cells’
Fens M, Larkin S, Scicinski J, Fitch W, Oronsky B, Kuypers F
Blood (ASH Annual Meeting Abstracts) 2012, 120: Abstract 3246

25.    ‘NO or No NO, Increased Reduction of Nitrite to Nitric Oxide by Modified Red Blood Cells’
Fens M, Larkin S, Morris C, Fitch W, Scicinski J, Oronsky B, Kuypers F
Blood (ASH Annual Meeting Abstracts) 2011, 118: Abstract 2125

26.    ‘Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials’
Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox S
Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, (676)
Proceedings: AACR 102nd Annual Meeting 2011– Apr 2-6, 2011; Orlando, FL

27.    ‘Disposition of 14C-RRx-001 in Rats after A Single Intravenous Administration and in Blood from Rats, Dogs, Monkeys, and Humans’
Scicinski J, Oronsky B, Fitch W, Taylor M, Luo Gang, Musick T, Marini J, Adams C, Schicker M, Gohdes M, McKenzie D, Ridgewell R
ISSX Annual meeting 2011, Abstract P81